2nd Pharma Partnering Conference
BOSTON | 2025
Driving Innovation Through Strategic Collaborations
key information
- Location: Wyndham Boston Beacon Hill 5 Blossom Street, Boston
- October 14-15, 2025
- 9:00 - 17:30 Local Time
Forging the Future of Pharma Through Collaboration
In today’s rapidly evolving pharmaceutical landscape, partnerships are not just strategic — they’re essential. From accelerating drug development to integrating cutting-edge technologies and improving patient outcomes, collaboration is the driving force behind industry innovation.
The 2nd Pharma Partnering Conference is where pharma leaders, biotech pioneers, and forward-thinking investors come together to spark conversations, strike deals, and shape the future of healthcare.
Why Attend?
Whether you represent a large pharmaceutical company looking to expand your pipeline, a biotech startup seeking your next strategic alliance, or an investor scouting for high-potential ventures, this conference delivers actionable insights and powerful connections.
This is more than a conference — it’s your opportunity to connect, collaborate, and innovate.
This event is designed for:
- Pharma executives leading external innovation and portfolio strategy
- Biotech founders looking to grow through strategic partnerships
- Investors seeking differentiated opportunities in life sciences
- Tech innovators building AI-driven solutions for the pharma value chain
- Service providers, legal experts, and academic liaisons enabling deal execution and development
Key Topics:
Conference Highlights:
- The Power of Partnerships: How collaboration across R&D, clinical development, and manufacturing is transforming the industry.
- Smart Deal-Making: Best practices for structuring deals that deliver long-term value.
- AI & Innovation in Practice: Real-world applications of AI in drug discovery, trial optimization, and diagnostics.
- Investor Perspectives: What today’s investors look for in early-stage biotech and how to stand out.
- Biotech–Pharma Synergies: Navigating the dynamics and complexities of cross-industry partnerships.
- Expert Keynotes from pharma executives, biotech founders, and leading investors.
- Interactive Panels exploring practical challenges in deal-making and innovation adoption.
- Innovation Spotlight Showcasing promising startups and emerging technologies.
- Power Hour Speed Connect High-energy, fast-paced networking to ignite new partnerships.
- 1-on-1 Meetings Dedicated networking sessions to explore concrete collaboration opportunities.
Everything you need to know about this event in one spot.
Check out our event overview and agenda and discover everything about this conference.
Event Speakers
Alex Chang
Senior Director, Business Development, Renal Pharmaceuticals
Fresenius Medical Care
Alex Zhavoronkov
CEO
Insilico Medicine
Amit Patel
Vice President
Indegene
Carla Bauer
Director, Oncology Search and Evaluation, Business Development & Licensing
Merck
Christiana Iyasere
Senior Director Technology Business Development and Accelerator
Dana-Farber Cancer Institute
Daksha Gupta
Manager
Indegene
Elena Diez Cecilia,
Senior Director, External Innovation, Discovery, Product Development and Supply (DPDS)
Johnson & Johnson
Ester Caffarel‑Salvador
Director, Strategic Innovation, Global Rare Diseases
Chiesi
Hong Xin
Senior Director, Oncology Scientific Innovation
Johnson & Johnson
Irene Blat
Senior Director, Search & Evaluation – Oncology
Servier Pharmaceuticals
Event Partners
Event Sponsor
LAXAI Life Sciences is a leading small molecule CRDMO providing end-to-end Integrated Drug Discovery, Development, and Manufacturing solutions to the pharmaceutical and biotech industries globally. With a focus on innovation, sustainability, and regulatory compliance, we leverage state-of-the-art infrastructure and a highly skilled scientific team to deliver efficient, scalable, and de-risked solutions. To date, we have successfully completed over 150 CMC projects and 20+ integrated discovery programs.
Event Sponsor
Indegene Limited is the tech-native, life sciences specialist orchestrating the path from commercialization strategy through activation. Trusted by 20 of the world’s top 20 biopharma companies across the value chain — from clinical and medical through commercial — Indegene helps life sciences leaders move at the speed of their ambition with #PractitionerLevelConfidence. Indegene’s difference comes from integrating deep domain knowledge, contextualized technology and operational excellence, built over 25 years.
Industry Pioneers Attending From
Testimonials
Rated 5 out of 5
Audience was great, maybe more variety in industry areas. It can be enlightening to learn from other industries
Delphine Demeestere
Director of External Innovation, Lonza
Rated 5 out of 5
You had CMOs, CROs, biotechs, and big pharma all in one room. That created richer discussions.
Romain Hahn
Global Partnering Lead, Roche
Rated 5 out of 5
Every conversation I had was relevant. I walked away with clear follow-up actions or next steps.
Benjamin Fischer
VP Global Alliance & Integration Management, STADA Group
Rated 5 out of 5
The Insilico talk on AI clearly showed how important solutions beyond the molecule are - to solve problems like improving adherence and reducing dropouts.
Marcel Wuethrich
Global Chief Commercial & Business Development Officer, evoleen
Rated 5 out of 5
It was especially interesting to hear from one of the companies that managed to move from AI into clinical development candidates.
Luis Correia
Founder and CEO, Basel Biotech Consulting Gmb
Rated 5 out of 5
The application of AI in drug development and the potential for future diagnostics - that’s a personal favorite. I truly believe it has the potential to revolutionize how we do drug development.
Isabella Visconti
Founder, Visconti Alliance Management
